DARE Share Price | Daré Bioscience, Inc. Stock Analysis & Recommendation

Q: What does Daré Bioscience, Inc. do?

Overview:Daré Bioscience, Inc. is a healthcare company focused on the development and commercialization of products in women’s reproductive health, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.Financial Snapshot:Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) Market-cap: USD 25.53 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 0.33 Return on Equity: 29.81% Price to Book: -2.67Contact Details:Address: 3655 Nobel Dr Ste 260, SAN DIEGO CA : 92122-1050 Tel: 1 858 9267655 Website: https://www.darebioscience.com/

Q: Is Daré Bioscience, Inc. overvalued or undervalued?

As of 13 May 2025, the valuation grade for Daré Bioscience, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued, with a Price to Book Value of -2.96 and an EV to EBITDA of -1.13, both of which reflect negative financial metrics. Additionally, the company's P/E ratio is not applicable due to its loss-making status.In comparison with peers, Daré Bioscience's valuation metrics are notably worse than those of Rezolute, Inc., which has a P/E of -4.90 and an EV to EBITDA of -3.46, and SELLAS Life Sciences Group, Inc., with a P/E of -5.74 and an EV to EBITDA of -4.57. The stark contrast in these ratios suggests that Daré is not only underperforming relative to its peers but also struggling to establish a viable valuation. Furthermore, the company's stock has significantly lagged behind the S&P 500, with a one-year return of -50.90% compared to the index's 10.26%, reinforcing the notion of overvaluation.

Q: Is Daré Bioscience, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for Daré Bioscience, Inc. has changed from bearish to mildly bearish. The weekly MACD is bearish, while the monthly MACD shows a mildly bullish stance. The weekly Bollinger Bands and KST are bearish, but the monthly KST is mildly bullish. The daily moving averages are bearish, indicating short-term weakness. The Dow Theory shows a mildly bullish trend on the weekly timeframe, but no trend on the monthly. Overall, the technical stance is mildly bearish, with mixed signals across different indicators.In terms of performance, the company has significantly underperformed the S&P 500 across all periods, with a year-to-date return of -33.33% compared to the S&P 500's 12.22%, and a one-year return of -35.60% versus the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

5.68 k

Shareholding (Sep 2025)

FII

0.29%

Held by 6 FIIs

DII

96.34%

Held by 3 DIIs

Promoter

0.00%

How big is Daré Bioscience, Inc.?

22-Jun-2025

As of Jun 18, Daré Bioscience, Inc. has a market capitalization of 25.53 million and reported net sales of 0.10 million with a net profit of -2.93 million over the latest four quarters. Shareholder's funds are at -6.01 million, and total assets amount to 22.10 million.

View full answer

What does Daré Bioscience, Inc. do?

22-Jun-2025

Daré Bioscience, Inc. is a micro-cap healthcare company focused on developing and commercializing products for women’s reproductive health. As of March 2025, it reported net sales of $0 million and a net loss of $4 million, with a market cap of $25.53 million.

View full answer

Who are in the management team of Daré Bioscience, Inc.?

22-Jun-2025

As of March 2022, the management team of Daré Bioscience, Inc. is led by Dr. William Rastetter (Independent Chairman) and Ms. Sabrina Johnson (President and CEO), supported by several independent directors including Dr. Cheryl Blanchard, Ms. Jessica Grossman, Mr. Steve Hall, Dr. Susan Kelley, and Mr. Gregory Matz.

View full answer

Is Daré Bioscience, Inc. overvalued or undervalued?

25-Jun-2025

As of May 13, 2025, Daré Bioscience, Inc. is considered overvalued with negative financial metrics and a valuation grade of "does not qualify," significantly underperforming compared to peers and the S&P 500.

View full answer

Is Daré Bioscience, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Daré Bioscience, Inc. shows a mildly bearish technical trend with mixed signals across indicators, while significantly underperforming the S&P 500 with year-to-date and one-year returns of -33.33% and -35.60%, respectively.

View full answer

Compare Daré Bioscience, Inc. with Similar Stocks

Fortress Biotech, Inc.Sol-Gel Technologies Ltd.Kineta, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 21 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-5.38

Return on Equity

-582.07%

Price to Book

7.35

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Sep 2025)

Net Profit:

-4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-35.48%

6 Months

-34.58%

1 Year

-51.39%

2 Years

-75.61%

3 Years

37.25%

4 Years

-92.62%

5 Years

-93.73%

Daré Bioscience, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.98%

EBIT Growth (5y)

1.98%

EBIT to Interest (avg)

-26.98

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.33

Sales to Capital Employed (avg)

-0.11

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

8.52%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

7.35

EV to EBIT

-0.34

EV to EBITDA

-0.37

EV to Capital Employed

-0.45

EV to Sales

5.64

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-582.07%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 4 Schemes (3.37%)

Foreign Institutions

Held by 6 Foreign Institutions (0.29%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 10.00% vs 9.09% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.10",
          "val2": "-3.20",
          "chgp": "3.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.30",
          "chgp": "-33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.60",
          "val2": "-4.00",
          "chgp": "10.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,623,407.60%",
          "val2": "0.00%",
          "chgp": "-1,62,340.76%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -72.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 86.42% vs 2.27% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "2.80",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.80",
          "val2": "-30.80",
          "chgp": "25.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "-0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.10",
          "val2": "-30.20",
          "chgp": "86.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,386,701.20%",
          "val2": "-10,983.30%",
          "chgp": "-2,37,571.79%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

0.00

-0.00

Operating Profit (PBDIT) excl Other Income

-3.10

-3.20

3.13%

Interest

0.20

0.30

-33.33%

Exceptional Items

0.00

Consolidate Net Profit

-3.60

-4.00

10.00%

Operating Profit Margin (Excl OI)

-1,623,407.60%

0.00%

-1,62,340.76%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 10.00% vs 9.09% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

2.80

-100.00%

Operating Profit (PBDIT) excl Other Income

-22.80

-30.80

25.97%

Interest

0.00

Exceptional Items

-0.10

Consolidate Net Profit

-4.10

-30.20

86.42%

Operating Profit Margin (Excl OI)

-2,386,701.20%

-10,983.30%

-2,37,571.79%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -72.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 86.42% vs 2.27% in Dec 2023

All Annual Results

Company CV

About Daré Bioscience, Inc.

Daré Bioscience, Inc.

Pharmaceuticals & Biotechnology

Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.

Company Coordinates

Company Details

3655 Nobel Dr Ste 260 , SAN DIEGO CA : 92122-1050

Tel: 1 858 9267655

https://www.darebioscience.com/

Registrar Details